AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia.

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report), ...

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

The US Food and Drug Administration (FDA) recently approved a new medication treatmeant, called Cobenfy, which is a ...